Research Article: New Research | Integrative Systems

Inhibiting Production of New Brain Cells during Puberty or Adulthood Blunts the Hormonally Induced Surge of Luteinizing Hormone in Female Rats

Late-born brain cells participate in the LH surge

Margaret A. Mohr¹, Lydia L. DonCarlos² and Cheryl L. Sisk¹

¹Neuroscience Program, Michigan State University, East Lansing, MI 48824, USA
²Department of Cell and Molecular Physiology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA

DOI: 10.1523/ENEURO.0133-17.2017

Received: 17 April 2017
Revised: 9 October 2017
Accepted: 16 October 2017
Published: 23 October 2017

Author contribution statement: MM, LLDC and CLS designed the experiments; MM conducted the experiments and analyses; MM, LLDC and CLS wrote the manuscript.

Funding: http://doi.org/10.13039/100000025HHS | NIH | National Institute of Mental Health (NIMH) R01MH090091

Conflict of Interest: Authors report no conflict of interest.

HHS | NIH | National Institute of Mental Health (NIMH), R01MH090091

L.L.D. and C. L. S. co-senior authors.

Correspondence should be addressed to Neuroscience Program, Michigan State University, East Lansing MI 48824, E-mail: sisk@msu.edu

Cite as: eNeuro 2017; 10.1523/ENEURO.0133-17.2017

Alerts: Sign up at eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.

Accepted manuscripts are peer-reviewed but have not been through the copyediting, formatting, or proofreading process.

Copyright © 2017 Mohr et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Inhibiting production of new brain cells during puberty or adulthood blunts the hormonally induced surge of luteinizing hormone in female rats

Margaret A. Mohr¹,³, Lydia L. DonCarlos²,#, and Cheryl L. Sisk¹,⁴,#

¹Neuroscience Program, Michigan State University, East Lansing MI 48824 USA
²Department of Cell and Molecular Physiology, Loyola University Chicago, Stritch School of Medicine, Maywood IL 60153 USA
³Present address: 650 Charles E. Young Dr. S., Los Angeles, CA 90095-1763
⁴Corresponding author: sisk@msu.edu
#Co-senior authors

Abbreviated title: Late-born brain cells participate in the LH surge

Number of Figures: 6

Word count:
- Abstract: 213
- Significance Statement: 119
- Introduction: 658
- Discussion: 1725

Acknowledgements: We thank Jane Venier, Elaine Sinclair, Jenny Kim, Alexandra Belinky, Corey Calhoun, and Heather Whitman for technical assistance. We thank anonymous reviewers for their insightful comments. Supported by R01MH090091 to LLDC and CLS.

Author contribution statement: MM, LLDC and CLS designed the experiments; MM conducted the experiments and analyses; MM, LLDC and CLS wrote the manuscript. The authors have no financial interests or conflicts of interest to disclose.
New cells are added during both puberty and adulthood to hypothalamic regions that govern reproduction, homeostasis, and social behaviors, yet the functions of these late-born cells remain elusive. Here, we pharmacologically inhibited cell proliferation in ventricular zones during puberty or in adulthood and determined subsequent effects on the hormone-induced surge of luteinizing hormone (LH) in female rats. Initial neuroanatomical analyses focused on verifying incorporation, activation, and pharmacological inhibition of pubertally or adult born cells in the anteroventral periventricular nucleus (AVPV) of the hypothalamus because of the essential role of the AVPV in triggering the preovulatory LH surge in females. We first showed that approximately half of the pubertally born AVPV cells are activated by estradiol plus progesterone treatment, as demonstrated by Fos expression, and that approximately 10% of pubertally born AVPV cells express estrogen receptor alpha (ERα). Next, we found that mitotic inhibition through intracerebroventricular administration of cytosine beta-d-arabinofuranoside, whether during puberty or in adulthood, decreased the number of new cells added to the AVPV and the suprachiasmatic nucleus (SCN), and also blunted and delayed the hormone-induced LH surge. These studies do not prove, but are highly suggestive, that ongoing postnatal addition of new cells in periventricular brain regions, including the AVPV and SCN, may be important to the integrity of female reproduction.
We investigated the role of pubertally and adult-born hypothalamic cells in the generation of the ovarian hormone-induced luteinizing hormone (LH) surge, which triggers ovulation in female rodents. In the anteroventral periventricular nucleus, the neural site where ovarian hormones induce the LH surge, many postnatally added cells become mature neurons or glial cells, many are activated by hormones during the surge, and some express estrogen receptor alpha. Importantly, pharmacological knockdown of cell proliferation in ventricular niches, either during puberty or in adulthood, disrupts the LH surge. This study suggests a novel mechanism for both the pubertal establishment and adult maintenance of female reproductive function, namely the incorporation of postnatally born neurons and glia into neural circuits essential for female fertility.
INTRODUCTION

It is now indisputable that neurons and glia are added during both puberty and adulthood to limbic and hypothalamic regions that govern reproduction, homeostasis, and social behaviors, offering an unexpected mechanism for neural plasticity throughout the life span (Bernier et al., 2002; Rankin et al., 2003; Kokoeva et al., 2005; He and Crews, 2007; Mak et al., 2007; Ahmed et al., 2008; Antzoulatos et al., 2008; Fowler et al., 2008; Migaud et al., 2010; Cheng et al., 2011; Mohr and Sisk, 2013; Bless et al., 2014; Saul et al., 2014; Staffend et al., 2014; Migaud et al., 2015; Bless et al., 2016; Mohr et al., 2016; Jhaveri et al., 2017). Although clues about the function of these late-born cells can be gleaned from investigations of their molecular identities and the internal and external signals that activate them (Pencea et al., 2001; Matsuzaki et al., 2009; Pierce and Xu, 2010; Lee et al., 2012; Bless et al., 2014; Sousa-Ferreira et al., 2014; Bless et al., 2016; Chaker et al., 2016), it has been a challenge to directly link late-born cells with specific functions or behavior, in part because the relevant brain regions are associated with multiple functions.

Previous investigations of sex differences in late-born cell addition identified the anteroventral periventricular nucleus (AVPV) as a hypothalamic cell group in which there are more pubertally born cells in females than in males (Ahmed et al., 2008; Mohr et al., 2016). The AVPV performs a pivotal function in females: it is a nodal point for the integration of signals from the brain and ovaries that govern ovulation (Wiegand and Terasawa, 1982; Petersen and Barraclough, 1989). Estrogens and progestins, produced by the ovaries and the brain (Micevych and Sinchak, 2008; Terasawa and Kenealy, 2012),
drive AVPV neurons to compel another small, scattered, and essential group of neurons
to release a surge of gonadotropin-releasing hormone (GnRH) into the pituitary portal
system, eliciting a surge of luteinizing hormone (LH), which then triggers ovulation. In
rats, the GnRH surge is strictly timed by neural inputs to the AVPV from the
suprachiasmatic nucleus (SCN), the primary central circadian clock (Williams and
Kriegsfeld, 2012). Prepubertal female rats, adult females without a functioning AVPV,
and male rats all have substantial GnRH, but are incapable of generating a hormone-
driven GnRH surge from the brain, and therefore are incapable of mounting an LH surge
from the pituitary (Wiegand and Terasawa, 1982; Petersen and Barraclough, 1989). The
crucial function and relative tractability of the AVPV prompted us to ask whether
pubertally born AVPV cells are functionally incorporated into reproductively relevant
circuits, and more generally, is cell addition during puberty, or even during adulthood,
critical to regulation of the adult GnRH/LH surge?

These questions address fundamental processes of brain development and
maintenance of reproductive competence. Pubertally born cells may support the
pubertal gain of function in neuroendocrine positive feedback in females, without which
generation of the GnRH/LH surge may be impossible. Alternatively, cells born during
puberty or adulthood may help maintain cyclic function throughout female reproductive
life. An important clinical implication is that, if addition of new brain cells is important
to female reproduction, whether during puberty or adulthood, then agents that alter
this process in the brain, as well as the periphery, such as radiation or
chemotherapeutics, may result in infertility via actions on the nervous system (Muller, 2002).

Here we report a series of experiments that demonstrate hormone-driven activation of pubertally born AVPV cells, and, in a subset of these pubertally born cells, expression of estrogen receptor alpha (ERα), a critical link in generation of the GnRH and LH surge. Moreover, addition of new cells, not only to the AVPV, but also to the SCN, continues into adulthood in females. Reducing cell proliferation in ventricular zones, either during puberty or in adulthood, via intracerebroventricular (ICV) delivery of a mitotic inhibitor blunted and delayed the ovarian hormone-induced LH surge, suggesting a causal role for newly generated cells in adult female reproductive function.

METHODS

Animals

Animals were treated in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and with the approval of the Michigan State University Institutional Animal Care and Use Committee. Weanling (postnatal day 21, P21) and young adult (~P60) Sprague-Dawley female rats were ordered from Harlan (Madison, WI) and singly housed in 37.5 x 33 x 17 cm clear polycarbonate cages with ad libitum access to food (Teklad Rodent diet no. 8640; Harlan, Madison, WI) and water. Animals were maintained on a 14:10 light:dark cycle (lights off at 1600h). Animals were given a week to acclimate after arrival before experimental manipulation, with daily handling.
Experimental Design and Statistical Analyses

General methodological details for animals, treatments, procedures, and microscopic analyses for the following experiments follow this section. All statistics were calculated using IBM SPSS Statistics, version 22.

**Experiment 1. Are pubertally born AVPV cells activated (express Fos) during the hormonally induced LH surge?** Female rats received ICV infusions of the cell birth date marker 5-bromo-2′-deoxyuridine (BrdU) for 4 weeks, from postnatal day (P) 28-P56. On P56, rats were ovariectomized (isoflurane anesthesia, bilateral flank incisions) and allowed to recuperate for one week. Seven rats were treated with estradiol and progesterone to induce an LH surge, and six rats were treated with oil vehicle. On P65, approximately 6 hours after the progesterone (or oil) injection, rats were perfused. Brain tissue from these animals was used to determine if BrdU-immunoreactive (BrdU-ir, i.e., pubertally born) AVPV cells expressed Fos during the LH surge via double-label immunofluorescence. Group differences in the percent of BrdU-ir cells that were also Fos-ir were assessed using a one-way ANOVA with a between subjects design, with the percentage of BrdU-ir cells expressing Fos in 4 anatomically matched sections of the AVPV as the dependent variable and treatment (oil vs. hormones) as the independent variable. Cohen’s d, a measure of effect size, was calculated using the means and standard deviations for each group; effect size is considered large when Cohen’s d ≥ 0.8.

**Experiment 2. Do pubertally born AVPV cells express estrogen receptor alpha (ERα) or progesterone receptor (PR)?** ERα- and PR-expressing AVPV cells are critical for the ovarian hormone-induced LH surge (Radovick et al., 2012). Estradiol down-regulates
ERα in the preoptic area (DonCarlos et al., 1991; Simerly et al., 1996), but upregulates PR (DonCarlos et al., 1989; Simerly et al., 1996). Therefore, to optimize steroid receptor localization, one series of tissue sections from four ovariectomized, oil-treated rats in Experiment 1 was used for double-label immunofluorescence for BrdU and ERα, and one series from four ovariectomized, estradiol and progesterone-treated rats in Experiment 1 was used for double-label immunofluorescence for BrdU and PR. The percentage of BrdU-ir cells that were either ERα- or PR-positive in four anatomically matched sections through the AVPV was calculated.

Experiment 3. Does pharmacological inhibition of cell proliferation during puberty or adulthood affect the hormone-induced LH surge? Prior research showed that new cells are added to AVPV during the juvenile period and during early and mid-puberty (Ahmed et al., 2008), but whether postnatal addition of new cells to the rat AVPV extends beyond mid-puberty has not been investigated. To address this question, female rats received a four-week ICV infusion of the mitotic inhibitor cytosine beta-d-arabinofuranoside (AraC) or vehicle control (which contained BrdU), either during puberty (4-8 wk of age), or in young adulthood (9/10-13/14 wk of age). Rats treated during puberty were monitored daily upon arrival in the laboratory to determine the day of vaginal opening; all rats in this study were weighed daily throughout the experiment. After 4-weeks of ICV AraC or vehicle, rats were anesthetized with isoflurane, and minipumps were removed. Following removal of minipumps, vaginal smears were collected daily for two weeks from five rats in each of the four groups before ovariectomy at 10 (pubertal treatment) or 15-16 (adult treatment) weeks of age.
The remaining rats in each group were ovariectomized at the time of removal of the minipumps (8 and 13 wk of age, pubertal and adult treatments, respectively). At the time of ovariectomy, all rats were fitted with rat femoral vein tapered catheters (Alzet cat no 0007745, Cupertino CA) for repeated blood sampling. After a 2-3 day recovery period, animals with patent catheters received hormone priming to induce an LH surge. After the progesterone injection at 1000 h, 200μl blood samples were obtained hourly from 1100 h until 1300 h, every half-hour from 1350-1500 h, and hourly from 1500 h-1900 h. At each blood collection, sterile saline (200 μl) was replaced via the catheter. Four-five days after the first induction of the LH surge, rats received hormone treatment to induce another LH surge, and were perfused 6 hours after the progesterone injection. Cannula placement was confirmed during brain sectioning; no animals had to be excluded from analyses for misplaced cannulae. For a timeline of this experiment, see Fig 6A.

Brain sections through the AVPV were used for either single-label BrdU immunohistochemistry, double-label immunofluorescence to determine whether BrdU-ir cells expressed Fos, or triple-label immunofluorescence to determine whether BrdU-ir cells expressed markers of mature neurons (NeuN) or astrocytes (GFAP). Animals with catheters that had lost patency could not be included in the analysis of the LH surge, but these animals were included in the tissue analyses for immunohistochemistry or immunofluorescence. The small number of AVPV sections available precluded performing double- and triple-label immunofluorescence in all rats, therefore these
procedures were performed in a subset of rats from each group. Final sample sizes for the different analyses are reported below.

To determine whether AraC treatment affected LH concentrations across time in pubertal- and adult-treated animals, a two-way repeated measures ANOVA was performed with LH concentration as the within-subjects factor and treatment (AraC vs. vehicle control) and age during treatment (puberty vs. adulthood) as the between subjects factors (n=4 pubertal-control; n=3 pubertal-AraC; n=4 adult-control; n=4 adult-AraC). Significant effects were followed up by Fisher’s LSD. Area Under Curve calculations were performed to determine whether the size of the LH surge differed between animals treated with AraC during puberty or adulthood compared with age-matched controls. To determine if AraC treatment affected the peak of the LH surge or the timing of the LH surge, the peak value of plasma LH was recorded along with the time that the peak occurred for each animal. Two-way ANOVAs (AraC/control and pubertal/adult treatment) were performed to determine if AraC treatment affected the maximum LH concentration or the time of the LH peak. These ANOVAs revealed a main effect of treatment in both instances, and Cohen’s d was calculated for these main effects to estimate effect size.

To compare the number of AVPV cells added during puberty vs adulthood, and to assess the effectiveness of AraC in interrupting cell proliferation, a two-way ANOVA with a between subjects design was performed with age during treatment (puberty or adulthood) and treatment (AraC or vehicle control) as the independent variables and the total number of BrdU-ir cells in 4 anatomically matched 30μm sections of the AVPV
as the dependent variable (n=7 pubertal control; 5 pubertal AraC; 6 adult control; 7 adult AraC). This ANOVA revealed main effects of both age during treatment and treatment, and Cohen’s d was calculated for each of these main effects to estimate effect sizes.

Our finding that AraC treatment resulted in a ~50 min delay of the LH surge (see Results) raised the possibility of SCN involvement, although neither we nor others that we know of had previously investigated whether cells are added postnatally to the SCN. Fortuitously, the series of sections used for single-label BrdU immunohistochemistry in this experiment included the two most rostral sections of the SCN, in most animals, and we quantified BrdU-ir cells in these sections as well (n=5, all groups).

To examine whether the proportion of AVPV BrdU-ir cells that were activated during the surge differed in pubertal and adult vehicle control groups, a between subjects one-way ANOVA was performed with age during treatment (puberty vs. adulthood) as the independent variable, and the percentage of BrdU-ir cells that were also Fos-ir in 4 anatomically matched sections of the AVPV as the dependent variable (n=3/age). Qualitative assessment of BrdU/NeuN or BrdU/GFAP colocalization was explored in 4 anatomically matched sections of the AVPV in AraC- or vehicle-treated animals (n=2/age/treatment). The percentage of BrdU-ir cells that were also NeuN-ir or GFAP-ir was calculated for each group but statistical analyses were not performed because of the small sample sizes.

LH surge induction and timing
We conducted a pilot study to determine the timing of a hormonally induced LH surge in female rats under our laboratory conditions. Adult female Sprague-Dawley rats (P60-P70; Harlan) were ovariectomized and fitted with femoral catheters with tethers, then 1 week later an LH surge was induced. To induce an LH surge, rats received injections of estradiol benzoate (EB; sc; 10 μg in 0.05 ml sesame oil) or vehicle for two consecutive days at 1000 h. On the third day, animals received progesterone (P; sc; 500 μg in 0.1 ml sesame oil) or oil at 1000 h. Blood was collected (200 μl) every hour starting the morning of P treatment, at 0800 h, then every 20 minutes from 1100 to 1300 h, then hourly until 0300 h, for a total of 24 samples per animal. Plasma LH concentrations were determined via RIA. After determining that the peak LH concentration was 35.1 ± 8.7 ng/ml at 1500 h, approximately 5 hours following the progesterone treatment, another LH surge was induced by EB and P treatment in four of the six rats used to determine the timing of the LH surge, and the remaining two received oil vehicle injections. All rats were perfused 6 hours after P or oil treatment, approximately one hour after the expected LH peak and when surge-induced Fos expression in the AVPV was expected to be maximal (Lee et al., 1990). Single-label Fos immunohistochemistry was performed and analyzed on sections through the AVPV as previously described (Romeo et al., 1998), but without nickel chloride in the diaminobenzidine solution. The density of Fos-ir AVPV cells was 3-4x higher in rats given EB/P compared with rats given oil, confirming that EB/P induction of an LH surge is associated with increased Fos expression in the AVPV. We used the same regimen of hormone treatment in the current experiments to
induce an LH surge; blood sampling and sacrifice time points selected for the current experiments were based on the results of this pilot experiment.

259 **Radioimmunoassay for LH**

Plasma LH concentrations were determined from duplicate 50 μl samples using Rat LH RIA kit from A.F. Parlow, (Scientific Director, National Hormone and Peptide Program. Harbor-UCLA Medical center, Torrance, CA) according to previously published methods (Sisk and Desjardins, 1986). The lower limit of detectability for the assay was 0.8 ng/ml; all values that fell below the assay sensitivity were adjusted to 0.8 ng/ml. The intraassay coefficient of variation was 11.0%. Samples from this assay that were above 30 ng/ml were re-run with either 10 μl or 25 μl plasma samples, with standard curves ranging from 1.6 ng/ml-60 ng/ml or 4 ng/ml-150 ng/ml, respectively, and with an intraassay coefficient of variation of 6.6%.

269 **Surgeries and drug treatments**

In Experiments 1 and 2, rats underwent stereotaxic surgery to receive unilateral ICV cannulas (Alzet Brain Infusion Kit 2, Cupertino CA) aimed at the lateral ventricle (1.00 mm posterior, 1.2 mm lateral, and 4.00 mm ventral from bregma) and attached to osmotic minipump implants designed to deliver 5-bromo-2'-deoxyuridine solution (BrdU; Sigma; 4.5 μg/μl) in sterile artificial cerebrospinal fluid (aCSF; Harvard Apparatus, AH 59-7316), 0.11 μl/hour for 28 days (Alzet model #1004). In Experiment 3, the mitotic inhibitor, AraC (Sigma; 33 μg/μl), was added to the BrdU/aCSF solution at the time of
ICV cannula implantation; age-matched control animals received BrdU vehicle solution alone.

The use of BrdU as a marker of cell proliferation in the female rat AVPV was validated in a previous study, which found that 2 hours after a systemic BrdU injection, virtually all BrdU-ir cells expressed proliferating nuclear cell antigen (Mohr et al., 2016).

Pilot studies on ICV delivery of BrdU and AraC showed that: a) in rats that received ICV BrdU for 4 weeks during puberty, abundant BrdU-labeled cells were observed in periventricular regions, but not in more lateral regions, including the medial amygdala; b) in rats that received peripheral BrdU injections and ICV AraC, AraC did not affect the number of BrdU-labeled cells in the medial amygdala, but did decrease the number of BrdU-labeled cells in periventricular regions. These results indicate that, when administered ICV, BrdU is incorporated into proliferating cells only in periventricular cytogenic niches, and similarly that ICV AraC inhibits cell proliferation only in periventricular cytogenic niches. Furthermore, these results suggest that areas other than those surrounding the ventricles are not involved in the effects of AraC on the LH surge.

Perfusions and tissue processing

Rats were sacrificed with an overdose of sodium pentobarbital (90 mg/kg, ip) and transcardially perfused with 4% paraformaldehyde. Brains were removed, post-fixed in 4% paraformaldehyde overnight, then switched to 30% sucrose in phosphate buffered saline until sectioning. Brains were coronally sectioned at 30 µm on a cryostat
and processed per previous reports (Ahmed et al., 2008) and standard protocols. A 1-in-
4 series of sections was mounted and Nissl-stained for reference.

**Single-label BrdU immunohistochemistry**

Single-label immunohistochemistry to detect BrdU was performed on a 1-in-4 series of free-floating sections according to published protocols (Ahmed et al., 2008; Mohr and Sisk, 2013), with minor modifications, i.e., no formamide or nickel was used and a blocking step was added using AffiniPure Fab Fragment donkey anti-rat IgG (Jackson ImmunoResearch, cat no. 712-007-003, 12 μg/ml; in TBS containing 0.1% Triton-X-100 and 3% donkey serum, Jackson ImmunoResearch). The primary antibody was a rat monoclonal primary anti-BrdU (Serotec, MCA2060; 1 μg/ml), and the secondary was Biotin-SP-conjugated AffiniPure donkey anti-rat IgG (Jackson ImmunoResearch, 712–065-150; 2 μg/ml).

Using brightfield illumination on an Olympus BX51 microscope equipped with Neurolucida (MBF Bioscience), the outline of the AVPV was first traced from adjacent Nissl-stained sections. The traces were superimposed onto the BrdU-ir sections, and BrdU-ir cells were counted bilaterally in 4 anatomically matched sections of the AVPV. BrdU-positive control tissue was used to confirm BrdU-immunoreactivity, and consisted of tissue from 1.5-2 month-old rats whose dam had received BrdU (200 mg/kg) during the latter end of gestation when the rate of embryonic neurogenesis is high. In addition, controls that excluded primary and secondary antibodies were run using experimental tissue that did not contain the AVPV (to conserve the small number of AVPV sections), and only minimal or no nonspecific background staining was
observed. This control tissue was included in all other immunohistochemical procedures described below.

**Double-label BrdU and Fos immunofluorescence**

BrdU and Fos were colocalized using immunofluorescence to detect activated cells. Previously published protocols were used (Mohr and Sisk, 2013) with the addition of a 10 min rinse in 0.1% sodium borohydride at the beginning of processing to reduce autofluorescence. The primary antibodies used were monoclonal rat anti-BrdU (Serotec, MCA2060; 1 μg/ml) and polyclonal rabbit anti-c-Fos (Santa Cruz, sc-52; 0.02 μg/ml). The secondary antibodies used were Biotin-SP-conjugated AffiniPure goat anti-rat (Jackson, 112-065-003; 1.3 μg/ml), Cy3-conjugated AffiniPure Goat anti-rabbit (Jackson, 111-165-144; 1.5 μg/ml), Cy2-conjugated streptavidin (Jackson, 016-220-084; 1.8 μg/ml) was used to visualize BrdU-immunoreactivity. Sections were mounted onto slides and coverslipped using SlowFade Gold antifade reagent (Life Technologies, cat no. S36936).

Twelve sections spanning the AVPV and rostral and caudal regions were taken from a 1-in-4 series and processed, and then 4 sections of the AVPV, anatomically matched across animals, were analyzed for BrdU/Fos colocalization. An Olympus BX51 microscope equipped with epifluorescence illumination and an MBF Bioscience Image Stack Module for Neurolucida were used to first trace the outline of the AVPV from adjacent Nissl-stained sections, and then the traces were superimposed onto the fluorescent sections. Z-stacks were taken using the MBF Bioscience Image Stack Module for Neurolucida at 0.5-micron steps spanning the Z-axis of BrdU-ir within the tissue using
an UPlanSApo 40× (0.9 NA) objective and epifluorescence filters to visualize BrdU-positive (FITC, EX480, BS505, EM535) and Fos-positive (TRITC, EX535, BS565, EM610) cells. The macroview was used to insure both accurate localization and lack of overlap of the stacks. Colocalization was confirmed using the 3D Visualization module to rotate images. Neurolucida software was used to quantify cells using a modified fractionator method. Minimal contrast adjustments were made to the images, but images were otherwise unaltered.

**Double-label BrdU/ERα or BrdU/PR immunofluorescence**

Sequential double-label immunofluorescence was used to colocalize BrdU and ERα or BrdU and PR. Tissue was rinsed in 0.05M TBS between all steps. Sections were incubated in 0.1% sodium borohydride for 10 min to reduce autofluorescence, then blocked in 1% hydrogen peroxide, 20% normal goat serum and 1% bovine serum albumin in TBS for 1 hour. For ER localization, the primary antiserum was rabbit anti-ERα (Millipore, C1355; 0.04 μg/ml) for 48 hours at 4°C. For PR localization, tissue was incubated in rabbit polyclonal antiserum directed against human PR (Dako, A009801-1; 1.2 μg/ml) for 72 hours at 4°C. Following incubation in primary antisera, tissue was rinsed and transferred to biotinylated goat-anti-rabbit IgG (Vector, BA-1000; 1.5 μg/ml) for 1 hour, then avidin/biotinylated enzyme complex reagent (ABC Elite Kit; Vector Laboratories) for 1 hour, then biotinyl tyramide (1:500 dilution with 1x amplification buffer from TSA Biotin System kit, Perkin Elmer, NEL700A001KT), and finally in Cy3-conjugated streptavidin (Jackson, 016-160-084; 3 μg/ml) for 1 hour. Tissue was then labeled for BrdU. After 30 min incubation in 2 N HCl at 37°C, tissue was rinsed in borate
buffer (pH 8.5) for 10 min, and then incubated with BrdU monoclonal rat anti-BrdU (48h at 4°C, then 1 hour in Cy2-conjugated goat anti-rat IgG; Jackson, 112-225-167; 1.5 μg/ml).

Microscopic analyses of BrdU and ERα or BrdU and PR were performed as described above for colocalization of BrdU and Fos. Data are expressed as percentage of BrdU-ir cells that were also ERα or PR positive.

Triple-label BrdU/NeuN/GFAP immunofluorescence

Triple label immunofluorescence for BrdU, the mature neuronal nucleus marker (NeuN), and the astrocyte marker, glial fibrillary acidic protein (GFAP) was performed on a 1-in-4 series of sections per animal as described above. Primary antibody incubations were for 48 hours at 4°C in a cocktail containing monoclonal rat anti-BrdU (Serotec, cat no. MCA2060; 1 μg/ml), monoclonal mouse anti-NeuN (Chemicon, cat no. MAB377, clone A60; 1 μg/ml), and polyclonal rabbit anti-GFAP (Dako, cat no. Z0334; 0.58 μg/ml) in TBS containing 0.3% Triton-X 100, 2% goat serum. Sections were incubated for 2h in a secondary antibody cocktail solution containing biotin-SP-conjugated AffiPure goat anti-rat (Jackson, cat no. 112 065 003; 1.3 μg/ml), Alexa Fluor 635 goat anti-mouse (Life Technologies, cat no. A-31574; 4 μg/ml) and Cy3-conjugated AffiniPure Goat anti-rabbit (Jackson, cat no. 111 165 144; 3 μg/ml), then for 1 hour in Cy2-conjugated streptavidin (Jackson, cat no. 016 220 084; 1.8 μg/ml), and then sections were mounted onto glass slides and coverslipped as above. Microscopic analysis to determine colocalization was performed as described above using a FITC filter to visualize BrdU, TRITC filter to visualize GFAP, and far red filter to visualize NeuN.
**RESULTS**

**Experiment 1. Pubertally born cells in the AVPV are activated by hormones**

BrdU and Fos were identified in AVPV sections using double-label immunofluorescence (Fig. 1A). The average (±SEM) total number of BrdU-ir cells/rat examined was 218.8 ± 37.6. In the vehicle-treated animals only 8 ± 3% of BrdU-ir cells in the AVPV were Fos-positive, whereas in the estrogen/progesterone-primed animals, 32 ± 3% of BrdU-ir cells in the AVPV were immunoreactive for Fos during the time of the expected LH surge (Fig. 1B; \( F(1,11) = 35.676, p \leq 0.0001 \)). Hormone induction of the LH surge resulted, therefore, in an approximately 4-fold increase in the proportion of pubertally born AVPV cells that were activated, indicating that a large subset (one third) of these cells are capable of responding to estradiol and progesterone (Cohen’s d = 3.35).

**Experiment 2. Some pubertally born AVPV cells express ERα, but none express PR.**

BrdU and ERα were identified in AVPV sections using double-label immunofluorescence. The average (±SEM) total number of BrdU-ir cells/rat examined was 166.6 ± 37.8. About 9 ± 1% of pubertally born cells in the AVPV displayed nuclear ERα-immunoreactivity (Fig. 2). Additionally, another 6 ± 1% of BrdU-ir cells had ERα labeling that was not nuclear, but punctate and appeared to be membrane ERα (Fig. 2). No pubertally born BrdU-ir cells were immunoreactive for PR in the AVPV, although PR positive, BrdU negative cells were abundant (Fig. 2).
Experiment 3. Addition of cells to the AVPV continues into adulthood. Inhibition of cell proliferation decreases cells added to AVPV during either puberty or adulthood.

The day of vaginal opening, a peripheral indicator of the start of puberty in female rats, did not differ between animals treated with AraC or vehicle solution during puberty (control, 35.6 ± 0.9 days of age, AraC, 36.5 ± 1; p > 0.5). Animal weights changed as a result of age but not treatment (in grams, at the time of sacrifice: pubertal control, 194.6 ± 6.3, pubertal AraC, 190.4 ± 10.0; adult control 221.6 ± 4.1, adult AraC, 212.4 ± 3.6; ANOVA significant effect of age, p < 0.001; no effect of treatment, p = 0.26; n = 7-8/group). Daily observations indicated that general health was unaffected by ICV AraC treatment.

The first key finding was that cells were added to the AVPV during puberty, as previously observed, but cells were also added to the AVPV during adulthood (Fig. 3A). Comparing the overall mean number of BrdU-ir cells, there were approximately 41% more pubertally born cells than adult born cells (Fig. 3B; main effect of age during treatment), \( F(1,21) = 6.687, p = 0.017; \) Cohen’s \( d = 0.88, \) large effect size, indicating that cell addition to the AVPV declines between puberty and adulthood. Next, as expected, inhibition of cell proliferation with ICV AraC treatment reduced the mean number of BrdU-ir cells in the AVPV, by an overall average of 58% (Fig. 3B; main effect of treatment, \( F(1,21) = 16.648, p = 0.001; \) Cohen’s \( d = 2.1, \) large effect size). We did not have enough power to detect an interaction between AraC treatment and age (\( F(1, 21) = 0.8566, p = 0.3652 \)), however visual inspection of the data suggests that AraC treatment was more effective at inhibiting cell proliferation during adulthood than
during puberty (81% vs. 40% knockdown of BrdU-ir cells compared to controls in adult-
vs pubertal-treated rats, respectively).

Finally, quantification of BrdU-ir cells in the two rostral SCN sections available for
analysis revealed a similar pattern of results as seen in the AVPV: a) more cells are
added to the SCN during puberty (mean ± SEM = 104.8 ± 21.4, pubertal-vehicle control)
than in adulthood (68.6 ± 9.4, adult-vehicle control; main effect of treatment age
(F(1,16) = 8.945, p = 0.009; Cohen’s d = 0.98); and b) AraC treatment reduced the
number of BrdU-ir SCN cells (main effect of treatment F(1,16) = 6.732, p = 0.019;
Cohen’s d = 1.71), whether administered during puberty (75.0 ± 21.9, pubertal-AraC) or
in adulthood (14.6 ± 4.4, adult-AraC).

Experiment 3. Adult-born AVPV cells can be activated. A subpopulation of both
pubertally born and adult-born AVPV cells becomes neurons or astrocytes.

In the control groups (those that did not receive AraC), we asked whether AVPV
cells born during adulthood are activated by hormone priming at the time of the
expected LH surge, and whether the proportion of adult born cells that express Fos is
similar to that of pubertally born cells. Approximately 40-50% of pubertally born and
adult-born AVPV cells expressed Fos during the expected time of a hormone-induced LH
surge, with no significant difference between groups (Fig. 4).

The proportion of pubertally or adult-born cells (BrdU-ir) that differentiate into
neurons (BrdU-ir/NeuN-ir) or astrocytes (BrdU-ir/GFAP-ir), or were not identified as to
either phenotype (BrdU-ir only) was determined by triple-label immunofluorescence
(Fig 5A). The average (±SEM) total number of BrdU-ir cells/rat examined was 105 ± 36
pubertal-control, 41 ± 23 pubertal-AraC, 164 ± 31 adult-control, and 21.5 ± 3.5 adult-
AraC (n=2/group). Across groups, the average percentage of BrdU-ir only cells was 55%
(range 43-67%), BrdU-ir/GFAP-ir cells 37.5% (range 28-52%), and BrdU-ir/NeuN-ir cells
7.5% (range 2-13%) (Fig5B). Thus, at the time point examined, just under half of late-
born AVPV cells have differentiated into mature neurons or glia, with the majority of
these differentiated cells of glial phenotype. Small sample sizes precluded statistical
analysis. In addition, because BrdU was administered over a four week period of time,
BrdU-ir cell age at the time of tissue collection ranged from 6-9 weeks, and we do not
know whether or how cell age interacts with the potential for differentiation.

Experiment 3. Inhibition of cell proliferation, during puberty or early adulthood, alters
ovarian cyclicity and reduces and delays the LH surge

Inhibition of cell proliferation during either puberty or adulthood disrupted
ovarian cyclicity as determined by monitoring of vaginal cytology for two weeks after
discontinuation of AraC treatment. On average, pubertal and adult control rats
respectively had 2.2 and 2 days with exclusively nucleated cells clearly indicative of
proestrus, whereas pubertal and adult AraC-treated rats had on average only 0.6 and
1.2 proestrus days, respectively (main effect of treatment, F(1,16) = 6.86, p = 0.019;
Cohen’s d = 3.79).

Inhibition of cell proliferation during either puberty or adulthood blunted and
delayed the estradiol and progesterone-elicited LH surge (Fig. 6). A two-way ANOVA
(treatment x age during treatment) with repeated measures (LH concentrations at each
time point) revealed that, compared with vehicle, AraC reduced the overall LH
concentration at the time of the surge (Fig. 6B,C; $F(1,11) = 4.982, p = 0.047$). Age during treatment (pubertal vs. adult) did not affect overall LH concentrations ($F(1,11) = 1.228, p = 0.291$), and there was no interaction between treatment and age during treatment ($F(1,11) = 0.162, p = 0.695$). Area Under Curve calculations revealed that AraC treatment during puberty or during adulthood reduced the LH surge by 17% and 21%, respectively (data not shown). AraC treatment significantly reduced the average maximum LH concentration by 50% (Fig. 6D; two way ANOVA, main effect of treatment, $F(1,11) = 7.080, p = 0.022$; Cohen’s $d = 1.4$). Inhibition of cell proliferation delayed the timing of the LH peak by approximately 50 minutes (two way ANOVA, main effect of treatment, $F(1,11) = 4.82, p = 0.05$; Cohen’s $d = 1.1$). The LH peak occurred at 1352 h ± 16 minutes in control-treated animals (collapsed across age during treatment), whereas in AraC-treated animals the LH peak occurred at 1439 h ± 15 minutes (Fig. 6E).

**DISCUSSION**

We provide evidence that postnatally born periventricular cells are functional components of hormone-responsive, reproductively relevant neural circuitry that controls adult GnRH/LH release, a process critical to ovulation. First, we discovered that approximately 40% of AVPV cells born during puberty and adulthood are activated during a hormone-induced LH surge, suggesting that they may play a role in regulating the surge. Second, we demonstrated that inhibiting cell proliferation, during either puberty or adulthood, decreases the number of pubertally and adult-born AVPV and SCN cells, alters ovarian cyclicity, and blunts and delays the LH response to ovarian
hormones, indicating that new cells are necessary for the full LH response. Our findings suggest a causal link between postnatal renewal of populations of hypothalamic cells and the integrity of neuroendocrine processes vital to female reproduction.

Our primary focus was on late-born cells in the AVPV, because estrogen action in the AVPV is both necessary and sufficient for hormone induction of the LH surge (Petersen and Barraclough, 1989; Radovick et al., 2012). However, we cannot rule out the possibility that pubertally or adult-born cells in other brain regions may also contribute to the generation of the GnRH/LH surge. AraC treatment could not be targeted specifically to the AVPV, because the location of the progenitor cells destined for the AVPV is unknown. The third ventricle and circumventricular organs are now known to be cytogenic niches for production of new brain cells in adulthood, and it is likely that at least some late-born AVPV cells migrate there from ventricular proliferative zones (Perez-Martin et al., 2010); for reviews see: (Bennett et al., 2009; Migaud et al., 2010; Cheng, 2013). Therefore, we chose ICV as the route of AraC administration for the current studies, which could reduce addition of cells to any region in which new cells originate in ventricular proliferative zones. Indeed, our preliminary examination of BrdU-ir cells in the SCN provides the first evidence that new cells are added during puberty and in adulthood to the SCN, and that the progenitor cells are in periventricular regions reached by ICV AraC. Thus, the current study provides evidence that late-born AVPV and SCN cells contribute to regulation of the magnitude and timing of the LH surge, a parsimonious conclusion consistent with the well-established functions of these two brain regions. However, other cell types or brain regions affected by AraC could be
involved as well, e.g. tanycytes in the lining of the 3rd ventricle and the median
eminence that regulate GnRH release (Prevot et al., 2007), or cells in the arcuate
nucleus involved in negative feedback regulation of tonic GnRH/LH secretion (Blake et
al., 1974; Blake, 1977; Kauffman et al., 2007). However, if AraC disrupted cell addition
to the arcuate nucleus in the present study, it would seem unlikely to account for the
observed blunting of the LH surge, as disruption of negative feedback would predict
higher baseline (pre-surge) levels of LH in AraC-treated rats, which were not observed in
this study. Regardless, if late-born cells in brain regions other than the AVPV and SCN
are ultimately found to be involved in regulation of the LH surge, such evidence would
corroborate the idea proposed here that ongoing renewal of hypothalamic cells is
integral to female reproduction across the lifespan.

Mitotic inhibition decreased ovarian cyclicity and altered the LH surge, but did
not eliminate either. Although proliferation was decreased substantially by AraC in the
present studies, it was not completely eliminated, especially during puberty. Therefore,
future experiments should determine the impact of completely blocking cell addition up
to the time of induction of a surge. In addition, it will be important to determine
whether interfering with cell proliferation has consequences on fertility, i.e., a
decreased potential to become pregnant, given the disrupted cycles, or perhaps
decreases in the number of ruptured follicles and therefore fewer offspring due to the
lower level of LH secreted.
The lower number of proestrus days and the nearly 50% reduction in maximum
LH release caused by AraC treatment are not likely the result of untoward side effects of
AraC treatment. Kokoeva and others (Kokoeva et al., 2005), using higher doses of AraC than in the present study, demonstrated that ICV AraC is not cytotoxic, as has been reported using other paradigms (Sanz-Rodriguez et al., 1997), because following ICV AraC, no cell degeneration was detected in the brain parenchyma as determined by the cell death marker Fluoro-Jade. In the present study, body weight and overall health of the AraC-treated rats were normal, indicating that AraC was not merely degrading hypothalamic function, but was indeed acting as a mitotic inhibitor to reduce proliferation of neuronal precursor cells that give rise to neurons and glia that ultimately regulate the LH surge.

About 10-13% of pubertally or adult-born AVPV cells were identified as neurons (BrdU/NeuN) and 30-40% as astrocytes (BrdU/GFAP). Pubertally born neurons could conceivably be kisspeptin neurons, given that the number of kisspeptin neurons in the AVPV markedly increases from P20 to adulthood, and that AVPV kisspeptin neuron signaling is required for estrogen positive feedback (Mayer et al., 2010). However, we were not able to determine whether this is the case because immunohistochemical labeling of kisspeptin protein in the rat AVPV requires pretreatment with colchicine (Franceschini et al., 2013). Newly born astrocytes might be among those that release neuroprogesterone in response to estrogen, an event critical for estrous cyclicity (Micevych et al., 2003). Because astrocytes in the prepubertal hypothalamus are not estrogen responsive (Kuo et al., 2010), and estrous cyclicity is established during puberty, we speculate that the higher number of astrocytes added during puberty than adulthood observed in this study may reflect the essential role of astrocytes in pubertal
maturation of neuroendocrine positive feedback. Many of the late-born AVPV cells that were not identified as either neurons or astrocytes in this study are likely to be microglia, which could also play a role in regulation of cyclic hormone release (Mohr et al., 2016). Some late-born cells may remain undifferentiated, perhaps performing a unique role in hypothalamic function, or may require additional signals to promote differentiation (e.g., exposure to males, pregnancy). Pubertally and adult-born neurons and glia may constitute a unique, as yet unidentified, cohort of cells that subserve the crucial functions of this evolutionarily essential brain region.

Many pubertally born cells were activated by hormone priming with estradiol and progesterone. Only a small subpopulation of pubertally born cells was steroid hormone receptor positive, suggesting that the hormones acted indirectly through older, hormone receptor-positive cells, then activating the Fos response in the newly born cells. The AVPV is rich in ERα-expressing cells (DonCarlos et al., 1991; Smith, 2013), including both neurons and astrocytes (Langub and Watson, 1992), whereas only approximately 10% of pubertally born cells in the AVPV displayed nuclear ERα immunoreactivity in this study. Even with the addition of the 6% of pubertally born cells in the current study that had distinct membrane ERα immunoreactivity, the proportion of pubertally born, ERα-expressing cells is lower than expected. Whether the pubertally born ERα-expressing cells are neurons or glia remains unknown. Although all PR positive cells in the AVPV also express ERα (Blaustein and Turcotte, 1989; Warembourg et al., 1989) not all ERα-expressing cells are PR positive; relatively few pubertally born cells were ERα positive, which may explain why none of them were PR immunoreactive.
The number of cells added to the AVPV was higher during puberty than in adulthood, and may reflect enhanced plasticity during this developmental phase (Juraska et al., 2013), when new social, behavioral, and neuroendocrine repertoires are acquired. While the mechanisms responsible for pubertal cell proliferation and survival are not fully known, earlier studies demonstrated that ovarian hormones drive the female-biased sex difference in the number of pubertally born AVPV cells, thus promoting the genesis and/or survival of pubertally born AVPV cells in females (Ahmed et al., 2008). A decline in cytogenesis from puberty to adulthood has been observed in other brain regions, including the dentate gyrus of the hippocampus (Okamoto et al., 2012), the nucleus accumbens, amygdala (Saul et al., 2014), hypothalamus (Haan et al., 2013; Zhang et al., 2017) and the prefrontal cortex (Staffend et al., 2014), and may reflect a general decline in cell renewal across the lifespan. If so, age-related waning in renewal of AVPV cells may contribute to a decrease in estrogen responsiveness and disruption of ovarian cyclicity in middle age. Indeed, in addition to depletion of follicles in the ovary, reproductive senescence has been attributed to altered hypothalamic signaling (Downs and Wise, 2009), as has aging in general (Zhang et al., 2017). We propose that ongoing postnatal addition of AVPV and SCN cells supports reproductive function during fertile periods of life, and that an age-related decrease in cell renewal is one mechanism underlying reproductive senescence. Establishing the function and incorporation of pubertally or adult-born cells into existing neural circuits has been a major challenge facing investigations of the neuro- and gliogenesis that continue beyond early development (Cameron and Glover, 2015;
Paredes et al., 2016). Although pubertal and adult neurogenesis has been recognized as an ongoing process that introduces new cells to the dentate gyrus and olfactory system, general acknowledgement of the functional relevance of addition of cells to other brain regions has lagged. This lack of recognition persists despite numerous reports demonstrating adult or pubertal cell addition in the hypothalamus (Kokoeva et al., 2005; Ahmed et al., 2008; Migaud et al., 2010; Perez-Martin et al., 2010; Cheng, 2013; Mohr and Sisk, 2013; Chaker et al., 2016; Mohr et al., 2016), amygdala (Ahmed et al., 2008; Fowler et al., 2008; Saul et al., 2014; Jhaveri et al., 2017), cerebral cortex (Snyder et al., 2009) and basal ganglia (Ernst et al., 2014; Staffend et al., 2014; Inta et al., 2015), among others. Furthermore, converging lines of evidence point to adult-born cells as functional components of hypothalamic circuitry involved in energy homeostasis (Kokoeva et al., 2005; Lee et al., 2012; Bless et al., 2014; Bless et al., 2016; Djogo et al., 2016; Rizzoti and Lovell-Badge, 2017). We now extend this growing body of evidence to include a function for late-born cells in a different hypothalamic role: reproduction. Our results serve to dispel the often-repeated dogma that incorporation of new cells is functionally limited to two regions, and provide evidence suggesting that pubertal and adult born cells functionally incorporate into a hypothalamic network of fundamental importance to survival of the species.
REFERENCES

Ahmed EI, Zehr JL, Schulz KM, Lorenz BH, DonCarlos LL, Sisk CL (2008) Pubertal hormones modulate the addition of new cells to sexually dimorphic brain regions. Nature Neuroscience 11:995-997.

Antzoulatos E, Magorien JE, Wood RI (2008) Cell proliferation and survival in the mating circuit of adult male hamsters: effects of testosterone and sexual behavior. Horm Behav 54:735-740.

Bennett L, Yang M, Enikolopov G, Iacovitti L (2009) Circumventricular organs: a novel site of neural stem cells in the adult brain. Mol Cell Neurosci 41:337-347.

Bernier PJ, Bedard A, Vinet J, Levesque M, Parent A (2002) Newly generated neurons in the amygdala and adjoining cortex of adult primates. Proc Natl Acad Sci U S A 99:11464-11469.

Blake CA (1977) A medial basal hypothalamic site of synergistic action of estrogen and progesterone on the inhibition of pituitary luteinizing hormone release. Endocrinology 101:1130-1134.

Blake CA, Norman RL, Sawyer CH (1974) Localization of inhibitory actions of estrogen and nicotine on release of luteinizing hormone in rats. Neuroendocrinology 16:22-35.

Blaustein JD, Turcotte JC (1989) Estradiol-induced progestin receptor immunoreactivity is found only in estrogen receptor-immunoreactive cells in guinea pig brain. Neuroendocrinology 49:454-461.

Bless EP, Reddy T, Acharya KD, Beltz BS, Tetel MJ (2014) Oestradiol and diet modulate energy homeostasis and hypothalamic neurogenesis in the adult female mouse. J Neuroendocrinol 26:805-816.

Bless EP, Yang J, Acharya KD, Nettles SA, Vassoler FM, Byrnes EM, Tetel MJ (2016) Adult neurogenesis in the female mouse hypothalamus: estradiol and high-fat diet alter the generation of newborn neurons expressing estrogen receptor alpha. eNeuro 3.

Cameron HA, Glover LR (2015) Adult neurogenesis: beyond learning and memory. Ann Rev Psychol 66:53-81.

Chaker Z, George C, Petrovska M, Caron JB, Lacube P, Caille I, Holzenberger M (2016) Hypothalamic neurogenesis persists in the aging brain and is controlled by energy-sensing IGF-I pathway. Neurobiol Aging 41:64-72.

Cheng MF (2013) Hypothalamic neurogenesis in the adult brain. Front Neuroendocrinol 34:167-178.

Cheng MF, Alexander K, Zhou S, Bonder E, Chuang LS (2011) Newborn GnRH neurons in the adult forebrain of the ring dove. Horm Behav 60:94-104.

Djogo T, Robins SC, Schneider S, Kryzskaya D, Liu X, Mingay A, Gillon CJ, Kim JH, Storch KF, Boehm U, Bourque CW, Stroh T, Dimou L, Kokoeva MV (2016) Adult NG2-glia are required for median eminence-mediated leptin sensing and body weight control. Cell Metab 23:797-810.
DonCarlos LL, Greene GL, Morrell JI (1989) Estrogen plus progesterone increases progestin receptor immunoreactivity in the brain of ovariectomized guinea pigs. Neuroendocrinology 50:613-623.

DonCarlos LL, Monroy E, Morrell JI (1991) Distribution of estrogen receptor-immunoreactive cells in the forebrain of the female guinea pig. J Comp Neurol 305:591-612.

Downs JL, Wise PM (2009) The role of the brain in female reproductive aging. Mol Cell Endocrinol 299:32-38.

Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, Possnert G, Druid H, Frisen J (2014) Neurogenesis in the striatum of the adult human brain. Cell 156:1072-1083.

Fowler CD, Liu Y, Wang Z (2008) Estrogen and adult neurogenesis in the amygdala and hypothalamus. Brain Res Rev 57:342-351.

Franceschini I, Yeo SH, Beltramo M, Desroziers E, Okamura H, Herbison AE, Caraty A (2013) Immunohistochemical evidence for the presence of various kisspeptin isoforms in the mammalian brain. J Neuroendocrinol 25:839-851.

Haan N, Goodman T, Najdi-Samiei A, Stratford CM, Rice R, El Agha E, Bellusci S, Hajihosseini MK (2013) Fgf10-expressing tanycytes add new neurons to the appetite/energy-balance regulating centers of the postnatal and adult hypothalamus. J Neurosci 33:6170-6180.

He J, Crews FT (2007) Neurogenesis decreases during brain maturation from adolescence to adulthood. Pharmacology Biochemistry and Behavior 86:327-333.

Inta D, Cameron HA, Gass P (2015) New neurons in the adult striatum: from rodents to humans. Trends Neurosci 38:517-523.

Jhaveri DJ, Tedoldi A, Hunt S, Sullivan R, Watts NR, Power JM, Bartlett PF, Sah P (2017) Evidence for newly generated interneurons in the basolateral amygdala of adult mice. Mol Psychiatry, ePub ahead of print.

Juraska JM, Sisk CL, DonCarlos LL (2013) Sexual differentiation of the adolescent rodent brain: hormonal influences and developmental mechanisms. Horm Behav 64:203-210.

Kauffman AS, Clifton DK, Steiner RA (2007) Emerging ideas about kisspeptin-GPR54 signaling in the neuroendocrine regulation of reproduction. Trends Neurosci 30:504-511.

Kokoeva MV, Yin H, Flier JS (2005) Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 310:679-683.

Kuo J, Hamid N, Bondar G, Dewing P, Clarkson J, Micevych P (2010) Sex differences in hypothalamic astrocyte response to estradiol stimulation. Biol Sex Differ 1:7.

Langub MC, Jr., Watson RE, Jr. (1992) Estrogen receptor-immunoreactive glia, endothelia, and ependyma in guinea pig preoptic area and median eminence: electron microscopy. Endocrinology 130:364-372.

Lee DA, Bedont JL, Pak T, Wang H, Song J, Miranda-Angulo A, Takiar V, Charubhumi V, Balordi F, Takebayashi H, Aja S, Ford E, Fishell G, Blackshaw S (2012) Tanycytes of
the hypothalamic median eminence form a diet-responsive neurogenic niche. Nat Neurosci 15:700-702.

Lee WS, Smith MS, Hoffman GE (1990) Luteinizing hormone-releasing hormone neurons express Fos protein during the proestrus surge of luteinizing hormone. Proc Natl Acad Sci U S A 87:5163-5167.

Mak GK, Enwere EK, Gregg C, Pakarainen T, Poutanen M, Huhtaniemi I, Weiss S (2007) Male pheromone-stimulated neurogenesis in the adult female brain: possible role in mating behavior. Nat Neurosci 10:1003-1011.

Matsuzaki K, Katakura M, Hara T, Li G, Hashimoto M, Shido O (2009) Proliferation of neuronal progenitor cells and neuronal differentiation in the hypothalamus are enhanced in heat-acclimated rats. Pflugers Arch 458:661-673.

Mayer C, Acosta-Martinez M, Dubois SL, Wolfe A, Radovick S, Boehm U, Levine JE (2010) Timing and completion of puberty in female mice depend on estrogen receptor alpha-signaling in kisspeptin neurons. Proc Natl Acad Sci U S A 107:22693-22698.

Micevych P, Sinchak K (2008) Estradiol regulation of progesterone synthesis in the brain. Mol Cell Endocrinol 290:44-50.

Micevych P, Sinchak K, Mills RH, Tao L, LaPolt P, Lu JK (2003) The luteinizing hormone surge is preceded by an estrogen-induced increase of hypothalamic progesterone in ovariectomized and adrenalectomized rats. Neuroendocrinology 78:29-35.

Migaud M, Butrille L, Batailler M (2015) Seasonal regulation of structural plasticity and neurogenesis in the adult mammalian brain: focus on the sheep hypothalamus. Front Neuroendocrinol 37:146-157.

Migaud M, Batailler M, Segura S, Duitoza A, Franceschini I, Pillon D (2010) Emerging new sites for adult neurogenesis in the mammalian brain: a comparative study between the hypothalamus and the classical neurogenic zones. Eur J Neurosci 32:2042-2052.

Mohr MA, Sisk CL (2013) Pubertally born neurons and glia are functionally integrated into limbic and hypothalamic circuits of the male Syrian hamster. Proc Natl Acad Sci USA 110:4792-4797.

Mohr MA, Garcia FL, DonCarlos LL, Sisk CL (2016) Neurons and glial cells are added to the female rat anteroventral periventricular nucleus during puberty. Endocrinology 157:2393-2402.

Muller J (2002) Disturbance of pubertal development after cancer treatment. Best Pract Res Clin Endocrinol Metab 16:91-103.

Okamoto M, Hojo Y, Inoue K, Matsui T, Kawato S, McEwen BS, Soya H (2012) Mild exercise increases dihydrotestosterone in hippocampus providing evidence for androgenic mediation of neurogenesis. Proc Natl Acad Sci U S A 109:13100-13105.

Paredes MF, Sorrells SF, Garcia-Verdugo JM, Alvarez-Buylla A (2016) Brain size and limits to adult neurogenesis. J Comp Neurol 524:646-664.

Pencea V, Bingaman KD, Wiegand SJ, Luskin MB (2001) Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new
neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 21:6706-6717.

Perez-Martín M, Cifuentes M, Grondona JM, Lopez-Avalos MD, Gomez-Pinedo U, García-Verdugo JM, Fernandez-Llebrez P (2010) IGF-I stimulates neurogenesis in the hypothalamus of adult rats. Eur J Neurosci 31:1533-1548.

Petersen L, Barralough C (1989) Suppression of spontaneous LH surges in estrogen-treated ovariectomized rats by microimplants of antiestrogens into the preoptic brain. Brain Res 484:279-289.

Pierce AA, Xu AW (2010) De novo neurogenesis in adult hypothalamus as a compensatory mechanism to regulate energy balance. J Neurosci 30:723-730.

Prevot V, Dehouck B, Poulain P, Beauvillain JC, Buee-Scherrer V, Bouret S (2007) Neuronal-glial-endothelial interactions and cell plasticity in the postnatal hypothalamus: implications for the neuroendocrine control of reproduction. Psychoneuroendocrinology 32 Suppl 1:S46-51.

Radovick S, Levine JE, Wolfe A (2012) Estrogenic regulation of the GnRH neuron. Front Endocrinol 3:52.

Rankin SL, Partlow GD, McCurdy RD, Giles ED, Fisher KR (2003) Postnatal neurogenesis in the vasopressin and oxytocin-containing nucleus of the pig hypothalamus. Brain Res 971:189-196.

Rizzoti K, Lovell-Badge R (2017) Pivotal role of median eminence tanycytes for hypothalamic function and neurogenesis. Mol Cell Endocrinol 445:7-13.

Romeo RD, Parfitt DB, Richardson HN, Sisk CL (1998) Pheromones elicit equivalent levels of Fos-immunoreactivity in prepubertal and adult male Syrian hamsters. Horm Behav 34:48-55.

Sanz-Rodriguez C, Boix J, Comella JX (1997) Cytosine arabinoside is neurotoxic to chick embryo spinal cord motoneurons in culture. Neurosci Lett 223:141-144.

Saul ML, Helreich DL, Callahan LM, Fudge JL (2014) Differences in amygdala cell proliferation between adolescent and young adult rats. Dev Psychobiol 56:517-528.

Simerly RB, Carr AM, Zee MC, Lorang D (1996) Ovarian steroid regulation of estrogen and progesterone receptor messenger ribonucleic acid in the anteroventral periventricular nucleus of the rat. J Neuroendocrinol 8:45-56.

Sisk CL, Desjardins C (1986) Pulsatile release of luteinizing hormone and testosterone in male ferrets. Endocrinology 119:1195-1203.

Smith JT (2013) Sex steroid regulation of kisspeptin circuits. Adv Exp Med Biol 784:275-295.

Snyder JS, Choe JS, Clifford MA, Jeurling SI, Hurley P, Brown A, Kamhi JF, Cameron HA (2009) Adult-born hippocampal neurons are more numerous, faster maturing, and more involved in behavior in rats than in mice. J Neurosci 29:14484-14495.

Sousa-Ferreira L, de Almeida LP, Cavadas C (2014) Role of hypothalamic neurogenesis in feeding regulation. Trends Endocrinol Metab 25:80-88.

Staffend NA, Mohr MA, DonCarlos LL, Sisk CL (2014) A decrease in the addition of new cells in the nucleus accumbens and prefrontal cortex between puberty and adulthood in male rats. Developmental Neurobiology 74:633-642.
Terasawa E, Kenealy BP (2012) Neuroestrogen, rapid action of estradiol, and GnRH neurons. Front Neuroendocrinol 33:364-375.

Warembourg M, Jolivet A, Milgrom E (1989) Immunohistochemical evidence of the presence of estrogen and progesterone receptors in the same neurons of the guinea pig hypothalamus and preoptic area. Brain Res 480:1-15.

Wiegand SJ, Terasawa E (1982) Discrete lesions reveal functional heterogeneity of suprachiasmatic structures in regulation of gonadotropin secretion in the female rat. Neuroendocrinology 34:395-404.

Williams WP, 3rd, Kriegsfeld LJ (2012) Circadian control of neuroendocrine circuits regulating female reproductive function. Front Endocrinol 3:60.

Zhang Y, Kim MS, Jia B, Yan J, Zuniga-Hertz JP, Han C, Cai D (2017) Hypothalamic stem cells control ageing speed partly through exosomal miRNAs. Nature 548:52-57.
Figure 1: Pubertally born cells were activated by estradiol and progesterone treatment. A) Representative images of a pubertally born cell that was also Fos-ir after a hormone-induced LH surge in adulthood. Images are a maximum intensity projection of a Z-stack (0.5 μm step) captured using the MBF Bioscience Image Stack Module. Scale bar indicates 10 μm. An orthogonal view (right) through the middle of the cell confirms colocalization; red arrow, x plane; green arrow, y plane; and blue arrow, z plane.

B) Hormone induction of the LH surge caused a significant increase in the percentage of pubertally born BrdU-ir cells that express Fos-ir (*p ≤ 0.0001). The graph represents means ± SEMs; for oil-treated, n = 6, for hormone-treated, n = 7.

Figure 2: Some pubertally born cells were ERα-immunoreactive, but none were PR-immunoreactive. Z-stack images in the AVPV of BrdU-ir cells colocalized with nuclear (top panel) and membrane-associated ERα-ir (middle panel). BrdU did not colocalize with PR (bottom panel). BrdU, ERα, mERα, PR, and Merge images are maximum intensity projections of 30 images (15 μm thick, 0.5 μm step). White scale bars represent 10 μm. In the column on the right, orthogonal views through the middle of the cells confirm colocalization (top two panels) or lack of colocalization (bottom panel); red arrow, x plane; green arrow, y plane; and blue arrow, z plane. Fluorescent labeling for BrdU/ERα performed on tissue from 4 ovariectomized and vehicle-treated rats; labeling for BrdU/PR was performed on tissue from 4 ovariectomized and estradiol- and progesterone-treated rats.

Figure 3: Fewer cells were added to the AVPV during adulthood than during puberty and the mitotic inhibitor, AraC, reduced the number of BrdU-ir cells in the AVPV. A) Representative images show BrdU-ir cells in the AVPV of female rats treated with vehicle (BrdU in aCSF) or AraC (in BrdU and aCSF vehicle) during puberty or adulthood. Scale bar indicates 100 μm. B) Graph depicts the quantitative results showing that on average, more cells were added to the AVPV during puberty than adulthood (main effect of age during treatment, *p = 0.017) and that on average, AraC reduced the number of BrdU-ir cells added to the AVPV (main effect of treatment, **p = 0.001). Graph represents means ± SEMs of the total number per animal of BrdU-ir cells in four anatomically matched sections through the AVPV; n = 7 for pubertal control, n = 5 for pubertal AraC, n = 6 for adult control, n = 7 for adult AraC.

Figure 4: Both pubertally born and adult born cells in the AVPV were activated in adulthood by hormone treatments designed to induce an LH surge. The graph depicts the percentage of pubertally or adult-born (BrdU-ir) cells in the AVPV that also express Fos-ir during the time of the LH surge in adult female rats that were treated with BrdU during puberty or during adulthood. Data are presented as mean ± SEM; n = 3/age.
Figure 5: Some cells in the AVPV that were born during puberty or adulthood had differentiated by 3 weeks, with or without AraC-treatment. A) Representative photomicrographs of pubertally born cells that were NeuN-ir or GFAP-ir. Images are maximum intensity projections of a Z-stack (0.5 μm step). Scale bars indicate 10 μm. Orthogonal views through the middle of the cells (right column) confirm colocalization; red arrow, x plane; green arrow, y plane; and blue arrow, z plane. B) Histograms represent the mean proportion of BrdU-ir cells that express GFAP, NeuN, or only BrdU immunoreactivity in animals receiving either vehicle (BrdU in aCSF) or AraC (AraC + BrdU in aCSF) ICV during puberty or adulthood (n = 2/age/treatment).

Figure 6: Knockdown of cell addition with AraC during puberty or adulthood reduced and delayed the LH surge. A) Experimental timeline. Pubertal (4 week old) or Adult (9-10 week old) female rats received ICV cannulae with osmotic minipumps containing AraC (33 μg/μl) and BrdU (4.5 μg/μl) in aCSF [AraC treatment group], or just BrdU in aCSF [Control treatment group]. Females were ovariectomized (OVX) after the end of ICV infusion and then primed with estradiol benzoate (EB; 10 μg in 0.05 ml sesame oil; s.c.) for two consecutive days at 1000 h, and then progesterone (P; 500 μg in 0.1 ml sesame oil; s.c.) on the third day at 1000h. Blood sampling occurred on the same day as P injection, from 1100 h to 1900 h. B) Pubertal or C) Adult AraC treatment reduced the LH surge across time (p = 0.047). Dotted vertical lines indicate lights off. Symbols above points indicate significant differences observed with Fishers LSD posthoc comparisons. D) AraC treatment reduced the maximum LH concentration (p = 0.022) compared with that observed in control animals. E) The LH peak was delayed in AraC-treated animals (p = 0.05), irrespective of age during treatment. Graphs represent means + SEMs; n = 4/grp, except for pubertal-AraC (n = 3). * represents p ≤ 0.05, + represents p ≤ 0.01.
A ICV Treatment

Vehicle (BrdU)  AraC

Age During Treatment

Puberty

Adulthood

B

Mean # BrdU-ir cells in AVPV

*

puberty  adulthood

control  AraC

**
A

Pubertal

4 puberty 8 adulthood 8-10

ICV AraC/ BrdU

LH Surge Induction
(OVX -- EB - EB - P; blood sampling)

Adult

9-10 adulthood 13-14 13-16

Weeks of Age

B

Treatment During Puberty

C

Treatment During Adulthood

[\text{LH}] (\text{ng/ml})

\begin{align*}
\text{Time} & \quad 1000 & 1200 & 1400 & 1600 & 1800 & 2000 \\
\text{[LH]} & \quad 0 & 0 & 0 & 0 & 0 & 0 \\
\end{align*}

\begin{align*}
\text{Time} & \quad 1000 & 1200 & 1400 & 1600 & 1800 & 2000 \\
\text{[LH]} & \quad 0 & 0 & 0 & 0 & 0 & 0 \\
\end{align*}

D

\begin{align*}
\text{Mean maximum [LH]} (\text{ng/ml}) & \quad 0 & 20 & 40 & 60 & 80 \\
\text{Treatment Time} & \quad \text{Puberty} & \text{Adult} \\
\hline
\text{Control} & \quad \text{AraC} \\
\end{align*}

E

\begin{align*}
1330 & \quad 1400 & \quad 1430 & \quad 1500 & \quad 1530 \\
\end{align*}